Biogen (BIIB) Tops Q4 EPS by 38c, Beats on Revenue; Offers FY26 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Biogen earnings preview Q4: set for weaker print, Leqembi outlook in focus
February 6, 2026 2:00 AM ESTInvesting.com-- Biogen is set to report a drop in fourth quarter earnings before the market open on February 6 on weaker sales in its multiple sclerosis drugs, although focus will be squarely on the companys pipeline, specifically its Alzheimers treatment Leqembi.
Biogen is expected to post earnings per share of $1.61 on revenue of $2.21 billion for the three months to December 31, Investing.com forecasts showed. This compares to EPS of $3.44 and revenue of $2.45 billion... More
